Prelude Therapeutics FY2024 net loss $127.2M; cash runway into Q2 2026

Prelude Therapeutics Inc

Net loss $127.2M ($1.68/share) vs $121.8M ($2.02/share) in FY2023; R&D expense rose to $118.0M.
Cash, equivalents and marketable securities $133.6M at Dec 31, 2024; runway into Q2 2026.
PRT3789 showed 5 confirmed partial responses in NSCLC, gastric, esophageal cancer; safety acceptable.
PRT7732 oral SMARCA2 degrader Phase 1 enrollment ongoing; interim data expected H2 2025.
Bryant Lim named permanent CFO; company to seek partner for PRT2527 CDK9 program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.